NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Net Income towards Common Stockholders of -$72.9 million for Q4 2025, down 628.11% year-on-year from $13.8 million in Q4 2024, and down 967.05% on a QoQ basis from -$6.8 million in Q3 2025.
NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 628.11% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 549.9% YoY) and the FY2024 annual result came in at $27.5 million, up 113.3% from the prior year.
- Net Income towards Common Stockholders declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for NBP reached as high as $33.3 million in Q3 2023 and fell as low as -$72.9 million in Q4 2025.
- A 3-year average of -$6.9 million and a median of -$4.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 66.68% in 2025 against a maximum downside of 4233946.15% in 2025.
- Year by year, Net Income towards Common Stockholders stood at $33.3 million in 2023, then tumbled by 58.52% to $13.8 million in 2024, then tumbled by 628.11% to -$72.9 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$72.9 million, -$6.8 million, and -$5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | NovaBridge Biosciences | 397.57 Mn | 397.57 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | 13.80 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 130.00 |
| Mar 31, 2024 | -6.90 Mn |
| Sep 30, 2023 | 33.26 Mn |
| Jun 30, 2023 | 320.00 |
| Dec 31, 2020 | 157.16 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -54.14 Mn |
| Sep 30, 2019 | -35.10 Mn |